Tweets
cool stuff at #EULAR2025
RESET #RCT - #vagal #nerve #stimulation #VNS vs sham in
#RA w 1or >1 #bDMARD-IR
N=242
D/C bDMARD,
on #csDMARD
#RA 12 yrs, 10SJC 12TJC
2.6 b/tsDMARD failure
Wk12 EULAR good/mod response
61v 42%
Sham▶️goes VNS ✅data=
@RheumNow @eular_org abst#OP190
Janet Pope @Janetbirdope ( View Tweet )
7 months 2 weeks ago
Intraarticular IL-1Ra Gene Therapy in Knee Osteoarthritis
In a dose-escalation trial in nine participants, they observed that a single intra-articular injection of the gene product led to an increase in IL-1Ra in the synovial fluid that remained elevated for up to a year. There https://t.co/qi0qHPd06j
Dr. John Cush @RheumNow ( View Tweet )
7 months 2 weeks ago
#polyrefractory #RA
=
failed all classes in #rheumatoid #arthritis
+inflammatory #arthritis
Longer disease duration
Late RA Rx
+power Doppler in POCUS
⬆️no refractory
BMI
Fibromyalgia - pain
⬇️SJC, less DAS , rapid X-ray progression
#EULAR2025 @RheumNow #D2T #RA https://t.co/1sPwf3Qa3m
Links:
Janet Pope @Janetbirdope ( View Tweet )
7 months 2 weeks ago
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty
Dr. John Cush @RheumNow ( View Tweet )
7 months 2 weeks ago
Transcranial Stimulation is Effective in Fibromyalgia
A randomized, controlled clinical trial in fibromyalgia (FM) has shown the efficacy of transcranial direct current stimulation (A-tDCS) (along with exercise and pain neuroscience education [PNE]), in alleviating the pain. https://t.co/P8SKs3JNEx
Dr. John Cush @RheumNow ( View Tweet )
7 months 2 weeks ago
🦵🏼💉LOSEIT study: liraglutide led to slight↑ in medial joint space width in knee OA vs placebo (0.22 vs 0.07 mm), but difference not statistically significant (p=0.17). More potent GLP-1RAs may be needed for greater improvement in structural knee OA
@RheumNow #EULAR2025 #OP0223
Mrinalini Dey @DrMiniDey ( View Tweet )
7 months 2 weeks ago
GRAPPA defines :
- D2T-PsA (failed ≥3 therapies incl. ≥2 b/tsDMARDs)
- CM(complex to manage)-PsA (adds pain, comorbidity, complexity).
A needed framework to improve trial design & real-world care.
Do these definitions fit your clinic?
#OP0175 @RheumNow #EULAR2025 https://t.co/ot1bVLIYLA
Jiha Lee @JihaRheum ( View Tweet )
7 months 2 weeks ago
#RITAZAREM: infection risk during RTX induction in AAV was ↑ w/ lung disease & nodules/cavities; ↓ w/ TMP-SMX prophylaxis. Early infections predicted later ones, but risk didn’t differ by RTX vs AZA. Pulmonary damage is a key red flag for infection
@RheumNow #EULAR2025 #OP0167
Mrinalini Dey @DrMiniDey ( View Tweet )
7 months 2 weeks ago
29% of new-onset psoriasis pts in Stockholm cohort developed PsA over 9,255 person-years.
Two prediction models (AUC 0.804) identify:
➡ who to refer
➡ who will progress
Key predictors: HLA-B27, CRP, enthesitis, arthralgia.
@RheumNow #EULAR2025 #OP0178:
Jiha Lee @JihaRheum ( View Tweet )
7 months 2 weeks ago
The definition of MAS. MAS is secondary HLH. Other causes of secondary HLH are infections, malignancy and iatrogenic.
Georgin-Lavialle S @RheumNow #EULAR2025 https://t.co/CpB78JBlVJ
Links:
Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
7 months 2 weeks ago
Clinical Pearl's for #MAS
Infections are still the most common cause.
Next is malignancy...
Then other causes like autoimmunity..
Ask a detailed history ! Sometimes check with the family when the pt can't give history..
#EULAR2025 @RheumNow https://t.co/fepercz5Af
Bella Mehta @bella_mehta ( View Tweet )
7 months 2 weeks ago
Total serum IL 18 can help instead of CDC42 or NLCR4 genetic testing in #MAS
Several monogentic mutations in primary HLH- these panels can be available..
#EULAR2025 @RheumNow
Bella Mehta @bella_mehta ( View Tweet )
7 months 2 weeks ago
